Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Evoke Pharma Inc (EVOK)
|
Add to portfolio |
|
|
|
| Price: |
$1.74
| | Metrics |
| OS: |
3.34
|
M
| |
|
|
| Market cap: |
$5.82
|
M
| |
|
|
|
Net cash:
|
$2.01
|
M
| |
$0.60
|
per share
|
|
EV:
|
$3.81
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($8.4)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 2.5 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 55.0% | 6929.0% | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 2.5 | 1.6 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 100.0% | -276.7% | | | | | |
| Selling, general and administrative | 10.3 | 9.8 | 6.4 | 3.7 | | | | |
| Research and development | 0.3 | 0.6 | 6.6 | 3.4 | 4.1 | 7.1 | 7.0 | 8.2 |
| General and administrative | | | | | 3.9 | 4.1 | 3.6 | 3.7 |
| EBIT | -8.7 | -8.9 | -13.0 | -7.2 | -8.0 | -11.2 | -10.5 | -11.8 |
| EBIT margin | -345.3% | -551.5% | -56678.3% | | | | | |
| Pre-tax income | -8.2 | -8.5 | -13.2 | -7.1 | -7.6 | -12.2 | -10.7 | -12.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -8.2 | -8.5 | -13.2 | -7.1 | -7.6 | -12.2 | -10.7 | -12.1 |
| Net margin | -327.8% | -527.7% | -57144.5% | | | | | |
| |
| Diluted EPS | ($2.62) | ($3.18) | ($0.52) | ($0.32) | ($0.46) | ($0.82) | ($1.15) | ($1.87) |
| Shares outstanding (diluted) | 3.1 | 2.7 | 25.5 | 22.3 | 16.6 | 15.0 | 9.3 | 6.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|